---
schema_version: "secwatch.filing_event.v1"
accession: "0001746473-24-000153"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2024-09-27T23:59:59+00:00"
generated_at: "2026-05-31T01:12:33.723886+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.05
calibrated_materiality_score: 0.05
confidence: "low"
source: SEC EDGAR
---

# Pliant Therapeutics amends bylaws to align with Delaware law and revise stockholder proposal procedures

## Summary
- Board approved Third Amended and Restated Bylaws effective September 24, 2024.
- Amendments align bylaws with Delaware law developments and include severability provision.
- Revised procedural and disclosure requirements for stockholder director nominations and other business proposals.
- Changes are ministerial and conforming; no substantive operational or financial impact.

## SEC filing metadata
- accession: 0001746473-24-000153
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2024-09-27T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.05
- calibrated_materiality_score: 0.05
- confidence: low
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000174647324000153/0001746473-24-000153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000174647324000153/plrx-20240924.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001746473-24-000153
- JSON: https://secwatch.observer/filing/0001746473-24-000153.json
- Plain text: https://secwatch.observer/filing/0001746473-24-000153.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.